初代ヒト肝細胞世界市場の見通し：詳細分析、予測(～2031年)

当レポートは、初代ヒト肝細胞 (Primary Human Hepatocytes) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

• 概要 初代ヒト肝細胞: 定義、特性、主要属性
• 市場セグメント：タイプ別
  • 世界の初代ヒト肝細胞 市場規模：タイプ別, 2020 VS 2024 VS 2031
  • Commercial Donor-Derived
  • Cadaveric Donor-Derived
  • iPSC-Derived Hepatocytes
• 市場セグメント：アプリケーション別
  • 世界の初代ヒト肝細胞 市場規模：用途別, 2020 VS 2024 VS 2031
  • Pharmaceutical & Biotech Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Hospitals & Clinical Settings
• 前提条件と制限
• 調査目的
• 対象期間

第2章 レポート概要

• 世界の初代ヒト肝細胞の収益 推定および予測 2020-2031
• 世界の初代ヒト肝細胞 収益：地域別
  • 収益比較: 2020 VS 2024 VS 2031
  • 収益実績と予測 地域別 (2020-2031)
  • 世界の収益市場シェア 地域別 (2020-2031)
  • 新興市場: 成長要因と投資動向

第3章 企業間の競争

• 世界の初代ヒト肝細胞 企業の収益ランキングと収益性
  • 世界の収益 (価格) ：競合別 (2020-2025)
  • 世界の主要企業の収益ランキング (2023 vs. 2024)
  • 収益ベースのTierセグメンテーション (Tier 1, Tier 2, and Tier 3)
  • 売上高総利益：トップ企業別 (2020 VS 2024)
• 世界の初代ヒト肝細胞 企業本社とサービス拠点
• 主要製品タイプ 市場規模：企業別
  • Commercial Donor-Derived Market Size by Players
  • Cadaveric Donor-Derived Market Size by Players
  • iPSC-Derived Hepatocytes Market Size by Players
• 世界の初代ヒト肝細胞 市場集中と力学
  • 世界の市場集中 (CR5 and HHI)
  • 新規参入／イグジットの影響分析
  • 戦略的な動き: M&A、事業拡大, 研究開発投資

第4章 世界の製品セグメンテーション分析

• 世界の初代ヒト肝細胞 収益動向 タイプ別
  • 世界の収益実績と予測 タイプ別 (2020-2031)
  • 世界の収益市場シェア：タイプ別 (2020-2031)
• 主要製品の属性と差別化
• サブタイプの力学: 成長リーダー、収益性、リスク
  • 高成長な特定分野と採用ドライバー
  • 収益ホットスポットとコストドライバー
  • 代替品の脅威

第5章 世界の下流アプリケーション分析

• 世界の初代ヒト肝細胞 収益：用途別
  • 世界の実績al andの収益予測：用途別 (2020-2031)
  • の収益市場シェア：用途別 (2020-2031)
  • 高成長アプリケーション識別
  • 新興アプリケーションのケーススタディ
• 下流 顧客分析
  • トップ顧客 地域別
  • トップ顧客 用途別

第6章 北米

• 北米の市場規模 (2020-2031)
• 北米の主要企業 収益 2024年
• 北米の初代ヒト肝細胞 市場規模：タイプ別 (2020-2031)
• 北米の初代ヒト肝細胞 市場規模：用途別 (2020-2031)
• 北米の成長促進要因と市場障壁
• 北米の初代ヒト肝細胞 市場規模：国別
  • 北米の収益動向：国別
  • US
  • カナダ
  • メキシコ

第7章 欧州

• 欧州の市場規模 (2020-2031)
• 欧州の主要企業 収益 2024年
• 欧州の初代ヒト肝細胞 市場規模：タイプ別 (2020-2031)
• 欧州の初代ヒト肝細胞 市場規模：用途別 (2020-2031)
• 欧州の成長促進要因と市場障壁
• 欧州の初代ヒト肝細胞 市場規模：国別
  • 欧州の収益動向：国別
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • ロシア

第8章 アジア太平洋地域

• アジア太平洋地域 市場規模 (2020-2031)
• アジア太平洋地域 主要企業 収益 2024年
• アジア太平洋地域 初代ヒト肝細胞 市場規模：タイプ別 (2020-2031)
• アジア太平洋地域 初代ヒト肝細胞 市場規模：用途別 (2020-2031)
• アジア太平洋地域 成長促進要因と市場障壁
• アジア太平洋地域 初代ヒト肝細胞 市場規模：地域別
  • アジア太平洋地域 収益動向 地域別
• 中国
• 日本
• 韓国
• オーストラリア
• インド
• 東南アジア
  • インドネシア
  • ベトナム
  • マレーシア
  • フィリピン
  • シンガポール

第9章 中南米

• 中南米 市場規模 (2020-2031)
• 中南米 主要企業 収益 2024年
• 中南米 初代ヒト肝細胞 市場規模：タイプ別 (2020-2031)
• 中南米 初代ヒト肝細胞 市場規模：用途別 (2020-2031)
• 中南米 投資機会と主な課題
• 中南米 初代ヒト肝細胞 市場規模：国別
  • 中南米 収益動向：国別 (2020 VS 2024 VS 2031)
  • ブラジル
  • アルゼンチン

第10章 中東・アフリカ

• 中東・アフリカの市場規模 (2020-2031)
• 中東・アフリカの主要企業 収益 2024年
• 中東・アフリカの初代ヒト肝細胞 市場規模：タイプ別 (2020-2031)
• 中東・アフリカの初代ヒト肝細胞 市場規模：用途別 (2020-2031)
• 中東・アフリカの投資機会と主な課題
• 中東・アフリカの初代ヒト肝細胞 市場規模：国別
  • 中東・アフリカの収益動向：国別 (2020 VS 2024 VS 2031)
  • 湾岸協力理事会諸国
  • イスラエル
  • エジプト
  • 南アフリカ

第11章 企業プロファイル

• Thermo Fisher Scientific (Gibco)
• ATCC
• Fujifilm Cellular Dynamics
• LifeNet Health LifeSciences
• ScienCell Research Laboratories
• iXCells Biotechnologies
• Axol Bioscience
• In Vitro ADMET Laboratories (IVAL)
• Preci
• Primacyt
• BeCytes Biotechnologies

第12章 初代ヒト肝細胞業界チェーン分析

• 初代ヒト肝細胞 産業チェーン
• 上流分析
  • 上流 主要サプライヤー
• 中流分析
• 下流 販売モデルと流通ネットワーク
  • 販売チャネル
  • 卸業者

第13章 初代ヒト肝細胞 市場動向

• 業界動向と進化
• 市場 成長ドライバーと新興の機会
• 市場の課題、リスク、抑制

第14章 主な調査結果 世界の初代ヒト肝細胞の主な市場調査結果

第15章 付録

List of Tables

Table 1. Global Primary Human Hepatocytes Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Primary Human Hepatocytes Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Primary Human Hepatocytes Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Primary Human Hepatocytes Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Primary Human Hepatocytes Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Primary Human Hepatocytes Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players'Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Primary Human Hepatocytes by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Human Hepatocytes as of 2024)

Table 11. Global Primary Human Hepatocytes Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Primary Human Hepatocytes Companies Headquarters

Table 13. Global Primary Human Hepatocytes Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) - Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Primary Human Hepatocytes Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Primary Human Hepatocytes Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Primary Human Hepatocytes Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Primary Human Hepatocytes Revenue by Application (2026-2031) & (US$ Million)

Table 21. Primary Human Hepatocytes High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Primary Human Hepatocytes Growth Accelerators and Market Barriers

Table 25. North America Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Primary Human Hepatocytes Growth Accelerators and Market Barriers

Table 27. Europe Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Primary Human Hepatocytes Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Primary Human Hepatocytes Investment Opportunities and Key Challenges

Table 31. Central and South America Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Primary Human Hepatocytes Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Primary Human Hepatocytes Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Thermo Fisher Scientific (Gibco) Corporation Information

Table 35. Thermo Fisher Scientific (Gibco) Description and Major Businesses

Table 36. Thermo Fisher Scientific (Gibco) Product Features and Attributes

Table 37. Thermo Fisher Scientific (Gibco) Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Thermo Fisher Scientific (Gibco) Revenue Proportion by Product in 2024

Table 39. Thermo Fisher Scientific (Gibco) Revenue Proportion by Application in 2024

Table 40. Thermo Fisher Scientific (Gibco) Revenue Proportion by Geographic Area in 2024

Table 41. Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes SWOT Analysis

Table 42. Thermo Fisher Scientific (Gibco) Recent Developments

Table 43. ATCC Corporation Information

Table 44. ATCC Description and Major Businesses

Table 45. ATCC Product Features and Attributes

Table 46. ATCC Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. ATCC Revenue Proportion by Product in 2024

Table 48. ATCC Revenue Proportion by Application in 2024

Table 49. ATCC Revenue Proportion by Geographic Area in 2024

Table 50. ATCC Primary Human Hepatocytes SWOT Analysis

Table 51. ATCC Recent Developments

Table 52. Fujifilm Cellular Dynamics Corporation Information

Table 53. Fujifilm Cellular Dynamics Description and Major Businesses

Table 54. Fujifilm Cellular Dynamics Product Features and Attributes

Table 55. Fujifilm Cellular Dynamics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Fujifilm Cellular Dynamics Revenue Proportion by Product in 2024

Table 57. Fujifilm Cellular Dynamics Revenue Proportion by Application in 2024

Table 58. Fujifilm Cellular Dynamics Revenue Proportion by Geographic Area in 2024

Table 59. Fujifilm Cellular Dynamics Primary Human Hepatocytes SWOT Analysis

Table 60. Fujifilm Cellular Dynamics Recent Developments

Table 61. LifeNet Health LifeSciences Corporation Information

Table 62. LifeNet Health LifeSciences Description and Major Businesses

Table 63. LifeNet Health LifeSciences Product Features and Attributes

Table 64. LifeNet Health LifeSciences Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. LifeNet Health LifeSciences Revenue Proportion by Product in 2024

Table 66. LifeNet Health LifeSciences Revenue Proportion by Application in 2024

Table 67. LifeNet Health LifeSciences Revenue Proportion by Geographic Area in 2024

Table 68. LifeNet Health LifeSciences Primary Human Hepatocytes SWOT Analysis

Table 69. LifeNet Health LifeSciences Recent Developments

Table 70. ScienCell Research Laboratories Corporation Information

Table 71. ScienCell Research Laboratories Description and Major Businesses

Table 72. ScienCell Research Laboratories Product Features and Attributes

Table 73. ScienCell Research Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. ScienCell Research Laboratories Revenue Proportion by Product in 2024

Table 75. ScienCell Research Laboratories Revenue Proportion by Application in 2024

Table 76. ScienCell Research Laboratories Revenue Proportion by Geographic Area in 2024

Table 77. ScienCell Research Laboratories Primary Human Hepatocytes SWOT Analysis

Table 78. ScienCell Research Laboratories Recent Developments

Table 79. iXCells Biotechnologies Corporation Information

Table 80. iXCells Biotechnologies Description and Major Businesses

Table 81. iXCells Biotechnologies Product Features and Attributes

Table 82. iXCells Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. iXCells Biotechnologies Recent Developments

Table 84. Axol Bioscience Corporation Information

Table 85. Axol Bioscience Description and Major Businesses

Table 86. Axol Bioscience Product Features and Attributes

Table 87. Axol Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. Axol Bioscience Recent Developments

Table 89. In Vitro ADMET Laboratories (IVAL) Corporation Information

Table 90. In Vitro ADMET Laboratories (IVAL) Description and Major Businesses

Table 91. In Vitro ADMET Laboratories (IVAL) Product Features and Attributes

Table 92. In Vitro ADMET Laboratories (IVAL) Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. In Vitro ADMET Laboratories (IVAL) Recent Developments

Table 94. Preci Corporation Information

Table 95. Preci Description and Major Businesses

Table 96. Preci Product Features and Attributes

Table 97. Preci Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Preci Recent Developments

Table 99. Primacyt Corporation Information

Table 100. Primacyt Description and Major Businesses

Table 101. Primacyt Product Features and Attributes

Table 102. Primacyt Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Primacyt Recent Developments

Table 104. BeCytes Biotechnologies Corporation Information

Table 105. BeCytes Biotechnologies Description and Major Businesses

Table 106. BeCytes Biotechnologies Product Features and Attributes

Table 107. BeCytes Biotechnologies Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. BeCytes Biotechnologies Recent Developments

Table 109. Raw Materials Key Suppliers

Table 110. Distributors List

Table 111. Market Trends and Market Evolution

Table 112. Market Drivers and Opportunities

Table 113. Market Challenges, Risks, and Restraints

Table 114. Research Programs/Design for This Report

Table 115. Key Data Information from Secondary Sources

Table 116. Key Data Information from Primary Sources

List of Figures

Figure 1. Primary Human Hepatocytes Product Picture

Figure 2. Global Primary Human Hepatocytes Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Commercial Donor-Derived Product Picture

Figure 4. Cadaveric Donor-Derived Product Picture

Figure 5. iPSC-Derived Hepatocytes Product Picture

Figure 6. Global Primary Human Hepatocytes Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Pharmaceutical & Biotech Companies

Figure 8. Contract Research Organizations (CROs)

Figure 9. Academic & Research Institutes

Figure 10. Hospitals & Clinical Settings

Figure 11. Primary Human Hepatocytes Report Years Considered

Figure 12. Global Primary Human Hepatocytes Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 14. Global Primary Human Hepatocytes Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global Primary Human Hepatocytes Revenue Market Share by Region (2020-2031)

Figure 16. Global Primary Human Hepatocytes Revenue Market Share Ranking (2024)

Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 18. Commercial Donor-Derived Revenue Market Share by Player in 2024

Figure 19. Cadaveric Donor-Derived Revenue Market Share by Player in 2024

Figure 20. iPSC-Derived Hepatocytes Revenue Market Share by Player in 2024

Figure 21. Global Primary Human Hepatocytes Revenue Market Share by Type (2020-2031)

Figure 22. Global Primary Human Hepatocytes Revenue Market Share by Application (2020-2031)

Figure 23. North America Primary Human Hepatocytes Revenue YoY (2020-2031) & (US$ Million)

Figure 24. North America Top 5 Players Primary Human Hepatocytes Revenue (US$ Million) in 2024

Figure 25. North America Primary Human Hepatocytes Revenue (US$ Million) by Type (2020 - 2031)

Figure 26. North America Primary Human Hepatocytes Revenue (US$ Million) by Application (2020-2031)

Figure 27. US Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 28. Canada Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 29. Mexico Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 30. Europe Primary Human Hepatocytes Revenue YoY (2020-2031) & (US$ Million)

Figure 31. Europe Top 5 Players Primary Human Hepatocytes Revenue (US$ Million) in 2024

Figure 32. Europe Primary Human Hepatocytes Revenue (US$ Million) by Type (2020-2031)

Figure 33. Europe Primary Human Hepatocytes Revenue (US$ Million) by Application (2020-2031)

Figure 34. Germany Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 35. France Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 36. U.K. Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 37. Italy Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 38. Russia Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 39. Asia-Pacific Primary Human Hepatocytes Revenue YoY (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Top 8 Players Primary Human Hepatocytes Revenue (US$ Million) in 2024

Figure 41. Asia-Pacific Primary Human Hepatocytes Revenue (US$ Million) by Type (2020-2031)

Figure 42. Asia-Pacific Primary Human Hepatocytes Revenue (US$ Million) by Application (2020-2031)

Figure 43. Indonesia Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 44. Japan Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 45. South Korea Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 46. Australia Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 47. India Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 48. Indonesia Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 49. Vietnam Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 50. Malaysia Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 51. Philippines Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 52. Singapore Primary Human Hepatocytes Revenue (2020-2031) & (US$ Million)

Figure 53. Central and South America Primary Human Hepatocytes Revenue YoY (2020-2031) & (US$ Million)

Figure 54. Central and South America Top 5 Players Primary Human Hepatocytes Revenue (US$ Million) in 2024

Figure 55. Central and South America Primary Human Hepatocytes Revenue (US$ Million) by Type (2020-2031)

Figure 56. Central and South America Primary Human Hepatocytes Revenue (US$ Million) by Application (2020-2031)

Figure 57. Brazil Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 58. Argentina Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 59. Middle East and Africa Primary Human Hepatocytes Revenue YoY (2020-2031) & (US$ Million)

Figure 60. Middle East and Africa Top 5 Players Primary Human Hepatocytes Revenue (US$ Million) in 2024

Figure 61. South America Primary Human Hepatocytes Revenue (US$ Million) by Type (2020-2031)

Figure 62. Middle East and Africa Primary Human Hepatocytes Revenue (US$ Million) by Application (2020-2031)

Figure 63. GCC Countries Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 64. Israel Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 65. Egypt Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 66. South Africa Primary Human Hepatocytes Revenue (2020-2025) & (US$ Million)

Figure 67. Primary Human Hepatocytes Industry Chain Mapping

Figure 68. Channels of Distribution (Direct Vs Distribution)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

This research report focuses on the Primary Human Hepatocytes Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Introduction to Primary Human Hepatocytes: Definition, Properties, and Key Attributes
• 1.2 Market Segmentation by Type
  • 1.2.1 Global Primary Human Hepatocytes Market Size by Type, 2020 VS 2024 VS 2031
  • 1.2.2 Commercial Donor-Derived
  • 1.2.3 Cadaveric Donor-Derived
  • 1.2.4 iPSC-Derived Hepatocytes
• 1.3 Market Segmentation by Application
  • 1.3.1 Global Primary Human Hepatocytes Market Size by Application, 2020 VS 2024 VS 2031
  • 1.3.2 Pharmaceutical & Biotech Companies
  • 1.3.3 Contract Research Organizations (CROs)
  • 1.3.4 Academic & Research Institutes
  • 1.3.5 Hospitals & Clinical Settings
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Primary Human Hepatocytes Revenue Estimates and Forecasts 2020-2031
• 2.2 Global Primary Human Hepatocytes Revenue by Region
  • 2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
  • 2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
  • 2.2.3 Global Revenue Market Share by Region (2020-2031)
  • 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

• 3.1 Global Primary Human Hepatocytes Player Revenue Rankings and Profitability
  • 3.1.1 Global Revenue (Value) by Players (2020-2025)
  • 3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
  • 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
  • 3.1.4 Gross Margin by Top Player (2020 VS 2024)
• 3.2 Global Primary Human Hepatocytes Companies Headquarters and Service Footprint
• 3.3 Main Product Type Market Size by Players
  • 3.3.1 Commercial Donor-Derived Market Size by Players
  • 3.3.2 Cadaveric Donor-Derived Market Size by Players
  • 3.3.3 iPSC-Derived Hepatocytes Market Size by Players
• 3.4 Global Primary Human Hepatocytes Market Concentration and Dynamics
  • 3.4.1 Global Market Concentration (CR5 and HHI)
  • 3.4.2 Entrant/Exit Impact Analysis
  • 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

• 4.1 Global Primary Human Hepatocytes Revenue Trends by Type
  • 4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
  • 4.1.2 Global Revenue Market Share by Type (2020-2031)
• 4.2 Key Product Attributes and Differentiation
• 4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
  • 4.3.1 High-Growth Niches and Adoption Drivers
  • 4.3.2 Profitability Hotspots and Cost Drivers
  • 4.3.3 Substitution Threats

5 Global Downstream Application Analysis

• 5.1 Global Primary Human Hepatocytes Revenue by Application
  • 5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
  • 5.1.2 Revenue Market Share by Application (2020-2031)
  • 5.1.3 High-Growth Application Identification
  • 5.1.4 Emerging Application Case Studies
• 5.2 Downstream Customer Analysis
  • 5.2.1 Top Customers by Region
  • 5.2.2 Top Customers by Application

6 North America

• 6.1 North America Market Size (2020-2031)
• 6.2 North America Key Players Revenue in 2024
• 6.3 North America Primary Human Hepatocytes Market Size by Type (2020-2031)
• 6.4 North America Primary Human Hepatocytes Market Size by Application (2020-2031)
• 6.5 North America Growth Accelerators and Market Barriers
• 6.6 North America Primary Human Hepatocytes Market Size by Country
  • 6.6.1 North America Revenue Trends by Country
  • 6.6.2 US
  • 6.6.3 Canada
  • 6.6.4 Mexico

7 Europe

• 7.1 Europe Market Size (2020-2031)
• 7.2 Europe Key Players Revenue in 2024
• 7.3 Europe Primary Human Hepatocytes Market Size by Type (2020-2031)
• 7.4 Europe Primary Human Hepatocytes Market Size by Application (2020-2031)
• 7.5 Europe Growth Accelerators and Market Barriers
• 7.6 Europe Primary Human Hepatocytes Market Size by Country
  • 7.6.1 Europe Revenue Trends by Country
  • 7.6.2 Germany
  • 7.6.3 France
  • 7.6.4 U.K.
  • 7.6.5 Italy
  • 7.6.6 Russia

8 Asia-Pacific

• 8.1 Asia-Pacific Market Size (2020-2031)
• 8.2 Asia-Pacific Key Players Revenue in 2024
• 8.3 Asia-Pacific Primary Human Hepatocytes Market Size by Type (2020-2031)
• 8.4 Asia-Pacific Primary Human Hepatocytes Market Size by Application (2020-2031)
• 8.5 Asia-Pacific Growth Accelerators and Market Barriers
• 8.6 Asia-Pacific Primary Human Hepatocytes Market Size by Region
  • 8.6.1 Asia-Pacific Revenue Trends by Region
• 8.7 China
• 8.8 Japan
• 8.9 South Korea
• 8.10 Australia
• 8.11 India
• 8.12 Southeast Asia
  • 8.12.1 Indonesia
  • 8.12.2 Vietnam
  • 8.12.3 Malaysia
  • 8.12.4 Philippines
  • 8.12.5 Singapore

9 Central and South America

• 9.1 Central and South America Market Size (2020-2031)
• 9.2 Central and South America Key Players Revenue in 2024
• 9.3 Central and South America Primary Human Hepatocytes Market Size by Type (2020-2031)
• 9.4 Central and South America Primary Human Hepatocytes Market Size by Application (2020-2031)
• 9.5 Central and South America Investment Opportunities and Key Challenges
• 9.6 Central and South America Primary Human Hepatocytes Market Size by Country
  • 9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 9.6.2 Brazil
  • 9.6.3 Argentina

10 Middle East and Africa

• 10.1 Middle East and Africa Market Size (2020-2031)
• 10.2 Middle East and Africa Key Players Revenue in 2024
• 10.3 Middle East and Africa Primary Human Hepatocytes Market Size by Type (2020-2031)
• 10.4 Middle East and Africa Primary Human Hepatocytes Market Size by Application (2020-2031)
• 10.5 Middle East and Africa Investment Opportunities and Key Challenges
• 10.6 Middle East and Africa Primary Human Hepatocytes Market Size by Country
  • 10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 10.6.2 GCC Countries
  • 10.6.3 Israel
  • 10.6.4 Egypt
  • 10.6.5 South Africa

11 Corporate Profile

• 11.1 Thermo Fisher Scientific (Gibco)
  • 11.1.1 Thermo Fisher Scientific (Gibco) Corporation Information
  • 11.1.2 Thermo Fisher Scientific (Gibco) Business Overview
  • 11.1.3 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes Product Features and Attributes
  • 11.1.4 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.1.5 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes Revenue by Product in 2024
  • 11.1.6 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes Revenue by Application in 2024
  • 11.1.7 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes Revenue by Geographic Area in 2024
  • 11.1.8 Thermo Fisher Scientific (Gibco) Primary Human Hepatocytes SWOT Analysis
  • 11.1.9 Thermo Fisher Scientific (Gibco) Recent Developments
• 11.2 ATCC
  • 11.2.1 ATCC Corporation Information
  • 11.2.2 ATCC Business Overview
  • 11.2.3 ATCC Primary Human Hepatocytes Product Features and Attributes
  • 11.2.4 ATCC Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.2.5 ATCC Primary Human Hepatocytes Revenue by Product in 2024
  • 11.2.6 ATCC Primary Human Hepatocytes Revenue by Application in 2024
  • 11.2.7 ATCC Primary Human Hepatocytes Revenue by Geographic Area in 2024
  • 11.2.8 ATCC Primary Human Hepatocytes SWOT Analysis
  • 11.2.9 ATCC Recent Developments
• 11.3 Fujifilm Cellular Dynamics
  • 11.3.1 Fujifilm Cellular Dynamics Corporation Information
  • 11.3.2 Fujifilm Cellular Dynamics Business Overview
  • 11.3.3 Fujifilm Cellular Dynamics Primary Human Hepatocytes Product Features and Attributes
  • 11.3.4 Fujifilm Cellular Dynamics Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.3.5 Fujifilm Cellular Dynamics Primary Human Hepatocytes Revenue by Product in 2024
  • 11.3.6 Fujifilm Cellular Dynamics Primary Human Hepatocytes Revenue by Application in 2024
  • 11.3.7 Fujifilm Cellular Dynamics Primary Human Hepatocytes Revenue by Geographic Area in 2024
  • 11.3.8 Fujifilm Cellular Dynamics Primary Human Hepatocytes SWOT Analysis
  • 11.3.9 Fujifilm Cellular Dynamics Recent Developments
• 11.4 LifeNet Health LifeSciences
  • 11.4.1 LifeNet Health LifeSciences Corporation Information
  • 11.4.2 LifeNet Health LifeSciences Business Overview
  • 11.4.3 LifeNet Health LifeSciences Primary Human Hepatocytes Product Features and Attributes
  • 11.4.4 LifeNet Health LifeSciences Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.4.5 LifeNet Health LifeSciences Primary Human Hepatocytes Revenue by Product in 2024
  • 11.4.6 LifeNet Health LifeSciences Primary Human Hepatocytes Revenue by Application in 2024
  • 11.4.7 LifeNet Health LifeSciences Primary Human Hepatocytes Revenue by Geographic Area in 2024
  • 11.4.8 LifeNet Health LifeSciences Primary Human Hepatocytes SWOT Analysis
  • 11.4.9 LifeNet Health LifeSciences Recent Developments
• 11.5 ScienCell Research Laboratories
  • 11.5.1 ScienCell Research Laboratories Corporation Information
  • 11.5.2 ScienCell Research Laboratories Business Overview
  • 11.5.3 ScienCell Research Laboratories Primary Human Hepatocytes Product Features and Attributes
  • 11.5.4 ScienCell Research Laboratories Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.5.5 ScienCell Research Laboratories Primary Human Hepatocytes Revenue by Product in 2024
  • 11.5.6 ScienCell Research Laboratories Primary Human Hepatocytes Revenue by Application in 2024
  • 11.5.7 ScienCell Research Laboratories Primary Human Hepatocytes Revenue by Geographic Area in 2024
  • 11.5.8 ScienCell Research Laboratories Primary Human Hepatocytes SWOT Analysis
  • 11.5.9 ScienCell Research Laboratories Recent Developments
• 11.6 iXCells Biotechnologies
  • 11.6.1 iXCells Biotechnologies Corporation Information
  • 11.6.2 iXCells Biotechnologies Business Overview
  • 11.6.3 iXCells Biotechnologies Primary Human Hepatocytes Product Features and Attributes
  • 11.6.4 iXCells Biotechnologies Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.6.5 iXCells Biotechnologies Recent Developments
• 11.7 Axol Bioscience
  • 11.7.1 Axol Bioscience Corporation Information
  • 11.7.2 Axol Bioscience Business Overview
  • 11.7.3 Axol Bioscience Primary Human Hepatocytes Product Features and Attributes
  • 11.7.4 Axol Bioscience Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.7.5 Axol Bioscience Recent Developments
• 11.8 In Vitro ADMET Laboratories (IVAL)
  • 11.8.1 In Vitro ADMET Laboratories (IVAL) Corporation Information
  • 11.8.2 In Vitro ADMET Laboratories (IVAL) Business Overview
  • 11.8.3 In Vitro ADMET Laboratories (IVAL) Primary Human Hepatocytes Product Features and Attributes
  • 11.8.4 In Vitro ADMET Laboratories (IVAL) Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.8.5 In Vitro ADMET Laboratories (IVAL) Recent Developments
• 11.9 Preci
  • 11.9.1 Preci Corporation Information
  • 11.9.2 Preci Business Overview
  • 11.9.3 Preci Primary Human Hepatocytes Product Features and Attributes
  • 11.9.4 Preci Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.9.5 Preci Recent Developments
• 11.10 Primacyt
  • 11.10.1 Primacyt Corporation Information
  • 11.10.2 Primacyt Business Overview
  • 11.10.3 Primacyt Primary Human Hepatocytes Product Features and Attributes
  • 11.10.4 Primacyt Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.10.5 Company Ten Recent Developments
• 11.11 BeCytes Biotechnologies
  • 11.11.1 BeCytes Biotechnologies Corporation Information
  • 11.11.2 BeCytes Biotechnologies Business Overview
  • 11.11.3 BeCytes Biotechnologies Primary Human Hepatocytes Product Features and Attributes
  • 11.11.4 BeCytes Biotechnologies Primary Human Hepatocytes Revenue and Gross Margin (2020-2025)
  • 11.11.5 BeCytes Biotechnologies Recent Developments

12 Primary Human HepatocytesIndustry Chain Analysis

• 12.1 Primary Human Hepatocytes Industry Chain
• 12.2 Upstream Analysis
  • 12.2.1 Upstream Key Suppliers
• 12.3 Middlestream Analysis
• 12.4 Downstream Sales Model and Distribution Networks
  • 12.4.1 Sales Channels
  • 12.4.2 Distributors

13 Primary Human Hepatocytes Market Dynamics

• 13.1 Industry Trends and Evolution
• 13.2 Market Growth Drivers and Emerging Opportunities
• 13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Primary Human Hepatocytes Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details